2023
“I’d like more options!”: Interviews to explore young people and family decision-making needs for pain management in juvenile idiopathic arthritis
Toupin-April K, Gaboury I, Proulx L, Huber A, Duffy C, Morgan E, Li L, Stringer E, Connelly M, Weiss J, Gibbon M, Sachs H, Sivakumar A, Sirois A, Sirotich E, Trehan N, Abrahams N, Cohen J, Cavallo S, Hindi T, Ragusa M, Légaré F, Brinkman W, Fortin P, Décary S, Lee R, Gmuca S, Paterson G, Tugwell P, Stinson J. “I’d like more options!”: Interviews to explore young people and family decision-making needs for pain management in juvenile idiopathic arthritis. Pediatric Rheumatology 2023, 21: 74. PMID: 37491246, PMCID: PMC10369758, DOI: 10.1186/s12969-023-00849-0.Peer-Reviewed Original ResearchConceptsPain management optionsHealth care providersParents/caregiversPain managementIdiopathic arthritisPediatric health care providersBackgroundJuvenile idiopathic arthritisPain management discussionsPediatric rheumatic conditionsOttawa Decision Support FrameworkHealth-related qualityJuvenile idiopathic arthritisQualitative descriptive study designYears of ageDecision support interventionsBetter health outcomesDescriptive study designEvidence-based informationManagement optionsQuality improvement networkRheumatology nursesRheumatology consultationJoint painHCP trainingNonpharmacological approaches
2021
Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
Gianfrancesco M, Leykina L, Izadi Z, Taylor T, Sparks J, Harrison C, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Hsu T, D’Silva K, Serling‐Boyd N, Wallwork R, Todd D, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J, Alliance T. Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry. Arthritis & Rheumatology 2021, 73: 374-380. PMID: 33146001, PMCID: PMC8467766, DOI: 10.1002/art.41567.Peer-Reviewed Original ResearchConceptsRheumatic diseasesGeneral US populationRace/ethnicityVentilatory supportLatinx patientsOdds ratioUS populationCOVID-19Rheumatic disease activityRheumatic disease diagnosisOdds of hospitalizationAfrican American patientsAssociation of raceCOVID-19 outcomesPhysician registryCoronavirus disease 2019COVID-19 hospitalizationMultivariable regression modelsSignificant health disparitiesNeeds of patientsInequitable health outcomesDisease activityHospitalized patientsMedication useWhite patients
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased odds